Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx Shifts Priorities Away From JAK Inhibitors, Puts More Emphasis on Carfilzomib

This article was originally published in The Pink Sheet Daily

Executive Summary

Onyx Pharmaceuticals opted out of a licensing agreement with Singapore's S*Bio for JAK2 inhibitors, while shifting more of its focus to proteasome inhibitor carfilzomib.
Advertisement

Related Content

Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates
Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates
Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File
Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File
What New Cancer Pathway Programs Mean For The Drug Industry
What New Cancer Pathway Programs Mean For The Drug Industry
Onyx Sees Blockbuster In Oncology Drug Carflizomib, Buys Proteolix To Get It
Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar
Onyx Accuses Bayer of a Double-Cross Over a Compound Related to Nexavar

Topics

Advertisement
UsernamePublicRestriction

Register

PS072322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel